{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:32:18Z","timestamp":1740115938049,"version":"3.37.3"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","award":["2E12"],"award-info":[{"award-number":["2E12"]}],"id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bmcl.2024.129840","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:58:10Z","timestamp":1717462690000},"page":"129840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PEG-lipid-modified agonistic antibody against tumor necrosis factor receptor family elicits superior apoptosis-inducing activity against human carcinoma"],"prefix":"10.1016","volume":"109","author":[{"given":"Takako","family":"Niwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kasuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihisa","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kurimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-4922","authenticated-orcid":false,"given":"Koji","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.129840_b0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/DDDT.S119036","article-title":"Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies","volume":"11","author":"Francoso","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmcl.2024.129840_b0010","first-page":"332","article-title":"Journey of TRAIL from bench to bedside and its potential role in immuno-oncology","volume":"11","author":"Naoum","year":"2017","journal-title":"Oncol Rev"},{"key":"10.1016\/j.bmcl.2024.129840_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116041","article-title":"Significance of TRAIL\/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: Implications for cancer-targeted therapeutics","volume":"221","author":"Maji","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2024.129840_b0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","article-title":"Apo2L\/TRAIL and its death and decoy receptors","volume":"10","author":"LeBlanc","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bmcl.2024.129840_b0025","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1158\/0008-5472.CAN-09-2889","article-title":"Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity","volume":"70","author":"Pavet","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2024.129840_b0030","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.4161\/19420862.2014.975099","article-title":"Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction","volume":"6","author":"Huet","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.bmcl.2024.129840_b0035","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1002\/anie.201511894","article-title":"An apoptosis-inducing peptidic heptad that efficiently clusters death receptor 5","volume":"55","author":"Valldorf","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bmcl.2024.129840_b0040","doi-asserted-by":"crossref","first-page":"8645","DOI":"10.1016\/j.biomaterials.2011.07.065","article-title":"Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery","volume":"32","author":"Fay","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.bmcl.2024.129840_b0045","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1016\/j.biomaterials.2012.06.024","article-title":"Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis","volume":"33","author":"Chu","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.bmcl.2024.129840_b0050","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jconrel.2016.05.041","article-title":"Lipid- and polyion complex-based micelles as agonist platforms for TNFR superfamily receptors","volume":"234","author":"Gilbreth","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.bmcl.2024.129840_b0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jconrel.2015.10.003","article-title":"Design of smart HPMA copolymer-based nanomedicines","volume":"240","author":"Yang","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.bmcl.2024.129840_b0060","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/91000","article-title":"Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity","volume":"7","author":"Ichikawa","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2024.129840_b0065","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/annonc\/mdn015","article-title":"A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes","volume":"19","author":"Yada","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmcl.2024.129840_b0070","first-page":"13","article-title":"Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)","volume":"25","author":"Forero-Torres","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.bmcl.2024.129840_b0075","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1021\/acs.molpharmaceut.7b01167","article-title":"Novel immunoliposome technology for enhancing the activity of the agonistic antibody against the tumor necrosis factor receptor superfamily","volume":"15","author":"Niwa","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmcl.2024.129840_b0080","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.onc.1206290","article-title":"Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK\/p38 and mitochondrial death pathway","volume":"22","author":"Ohtsuka","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bmcl.2024.129840_b0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/intimm\/12.4.555","article-title":"A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity","volume":"12","author":"Ichikawa","year":"2000","journal-title":"Int Immunol"},{"key":"10.1016\/j.bmcl.2024.129840_b0090","unstructured":"https:\/\/www.proteinatlas.org\/, Version: 23.0, Atlas updated: 2023-06-19."},{"key":"10.1016\/j.bmcl.2024.129840_b0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1423-0410.1979.tb02314.x","article-title":"Determination of polyethylene glycols 4000 and 6000 in plasma protein preparations","volume":"37","author":"Skoog","year":"1979","journal-title":"Vox Sang"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24002427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24002427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T13:42:55Z","timestamp":1719668575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24002427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":19,"alternative-id":["S0960894X24002427"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129840","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PEG-lipid-modified agonistic antibody against tumor necrosis factor receptor family elicits superior apoptosis-inducing activity against human carcinoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129840"}}